New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
07:40 EDTESRX, INSYInsys valuation could be $4 lower on Subsys exclusion, says Wells Fargo
After another research firm stated that Insys' (INSY) Subsys would be placed on Express Scripts' (ESRX) list of excluded drugs, Wells Fargo estimates that such a development could reduce Insys' valuation by about $4. The firm notes that the stock fell $4.16 on July 31 and August 1. It keeps an Outperform rating on the shares.
News For INSY;ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 16, 2014
08:22 EDTESRXExpress Scripts CFO change a 'modest' concern, says Leerink
Subscribe for More Information
07:47 EDTESRXExpress Scripts new CFO experience reassuring, says Oppenheimer
Subscribe for More Information
December 15, 2014
16:40 EDTESRXExpress Scripts backs FY14 EPS view $4.86-$4.90, consensus $4.88
Subscribe for More Information
16:39 EDTESRXExpress Scripts increases share repurchase authorization by 65M shares
Subscribe for More Information
16:37 EDTESRXExpress Scripts CFO Cathy Smith leaving company
Subscribe for More Information
07:40 EDTESRXExpress Scripts price target raised to $96 from $82 at UBS
Subscribe for More Information
07:12 EDTINSYInsys Therapeutics price target raised to $57 from $53 at RBC Capital
Subscribe for More Information
December 9, 2014
07:12 EDTINSYInsys Therapeutics receives FDA orphan drug designation for LEP-ETU
Insys Therapeutics announced that the FDA has granted orphan drug designation to its Liposome Entrapped Paclitaxel Easy to Use, or LEP-ETU, candidate for the treatment of gastric cancer. LEP-ETU is an improved formulation of paclitaxel, a widely used chemotherapeutic agent. Insys acquired LEP-ETU during its merger in 2010 with NeoPharm.
December 8, 2014
11:30 EDTESRXLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
10:35 EDTINSYInsys Therapeutics management to meet with Piper Jaffray
Subscribe for More Information
10:00 EDTINSYOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:18 EDTINSYInsys Therapeutics initiated with a Buy at Jefferies
Subscribe for More Information
December 4, 2014
11:03 EDTINSYInsys Therapeutics receives orphan status for gastric cancer treatment
The FDA said it granted Insys Therapeutics orphan status for its treatment of gastric cancer.
07:17 EDTINSYComparison study shows Insys synthetic CBD is identical to plant-based CBD
Independent comparison analyses have found that cannabidiol, or CBD, synthetically produced by Insys Therapeutics is chemically identical to plant-derived CBD. Analyses were conducted independently by Insys and the National Institute on Drug Abuse, or NIDA, part of the National Institutes of Health. The two separately-conducted analyses ascertained that Insys' synthetically produced CBD: Has identical identity and chemical structure to plant-derived CBD; Has identical stereochemistry to plant-derived CBD; both demonstrated the same CBD enantiomer with no enantiomer present, which was confirmed by Chiral Assay; Is more pure, with a 2% higher CBD Assay value than plant-derived CBD; Insys CBD total HPLC purity 99.9% vs. plant-derived CBD at 98.7%; and, Meets all ICH impurity guidelines, with no impurities greater than 0.10%, vs. plant-derived CBD which contained multiple impurities above ICH guidelines.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use